Grifols, the stock that has risen the most on the Ibex due to rumors of a possible second takeover bid by Brookfield

BarcelonaThe series about a possible takeover bid for Grifols isn't over. The proof is in its share price: the Catalan pharmaceutical company's shares, which had been battered for a few days, soared this Wednesday by up to 14% (at midday they were close to 6%) after the announcement of the acquisition. The Confidential has published that the Canadian fund Brookfield, which announced an agreement with the Grífols family last July to study a takeover bid –and that in September abandonment– is once again in talks with his family, through Morgan Stanley.

However, after the company published a relevant fact with the National Securities Market Commission (CNMV) stating that it is unaware of this information, the stock market rally has moderated, but the shares of the Catalan company have risen the most in Wednesday's session, up 3.8% per share.

The objective is to launch another takeover bid for 7 billion euros, according to this media, an offer 300 million higher than the one proposed last November, which stood at 10.5 euros per share and which the Catalan company's board of directors ultimately rejected as too low. "It would significantly undervalue the company's fundamental prospects and its long-term potential," the body stated at the time.

This same week, It was Grifols who launched a takeover bid to acquire the stake it did not yet hold in its German subsidiary Biotest.

Ending the turbulent times

The agreement announced in July with Brookfield came after a turbulent period for the pharmaceutical company, which worsened since January 2024 with the attack by the Gotham short fund, which in January accused Grifolsof falsifying their accountsThe company's share price was declining due to the outbreak of the pandemic - when it had to close its plasma collection centers - which forced it to implement a restructuring plan, which has resulted in many changes in management, such as the family's departure from command positions. In recent months, it has maneuvered to reduce its debt, which climbed to €9 billion.

When the possibility of taking the company private became public, sources close to the Grífols family explained that the family was "absolutely tired of the mistreatment in recent months" and the media exposure the company has received since the Gotham accusations. The idea was to take Grifols off the market for a while and return after a while.